SSIISS Innovations International, Inc.
The schedule
- Thu15Oct
Expected updates on FDA or international regulatory clearance milestones for SSII's surgical robotics systems.
- Sun31Jan
Q3 2026 print and preliminary outlook for 2027 top-line expansion, focusing on system placements and recurring instrument revenue.
- Mon15Mar
Updates on international market penetration, government health tenders, and potential new reimbursement codes supporting robotic procedures.
- Sun25Apr
Full-year 2026 financial results, providing insight into capital expenditure normalization and the company's trajectory toward profitability.
- Wed12May
First quarter 2027 results detailing recurring revenue streams from service and accessories alongside new system sales.
Past
- Wed5Aug
Q2 2026 results focusing on revenue growth from the robotic surgery platform, operating margin progress, and updates on cash burn trajectory.
- Wed15Jul
With shares near 52-week lows and elevated cash burn yielding roughly 4 quarters of runway, SSII faces a potential dilutive equity raise or strategic financing to extend its balance sheet.
- Wed13May
Actual outcome: Bear · $3.52 at outcome
SS Innovations reported in-line Q1 2026 EPS of -$0.01 alongside record quarterly revenue driven by strong growth in SSi Mantra installations and procedures. Despite these top-line achievements and recent successful telesurgery demonstrations, the stock fell 11.8% and broke below the $3.60 bear floor, as the results failed to convince the market that the company could sufficiently narrow its ongoing losses while sustaining its growth trajectory.
Q1 2026 earnings and an updated 2026 revenue outlook will test whether SS Innovations can sustain triple-digit top-line growth while narrowing losses at a $4.52 share price.
